Drug Trial Radar · NCT07940881
A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Nov 2028
Study completion Nov 2029
Sponsor
- Lead sponsor
- SystImmune Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.
Conditions
- Locally Advanced /Metastatic Solid Tumors
- Locally Advanced / Metastatic Solid Tumors
- First in Human
- Metastatic Solid Cancers
- Non Small Cell Lung Cancer
- NSCLC
- Lung Cancer (Diagnosis)
- Lung Cancer (NSCLC)
- Lung Cancer (Non-Small Cell)
- Lung Cancer (Locally Advanced or Metastatic)
- Melanoma (Skin Cancer)
- Ovarian Cancer
- Phase 1
- Phase 1 Clinical Trial
- Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC)
Interventions
SI-B037Drug
SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with Dose-Limiting ToxicitiesTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NEXT Oncology
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.